Michael Truett Tate - 06 Feb 2026 Form 4 Insider Report for Astera Labs, Inc. (ALAB)

Role: Chief Financial Officer
Signature: /s/ Philip Mazzara, Attorney-in-Fact
Issuer symbol: ALAB
Transactions as of: 06 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 10 Feb 2026, 18:52:38 UTC
Previous filing: 19 Nov 2025
Next filing: 19 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Tate Michael Truett	Chief Financial Officer	C/O ASTERA LABS, INC., 2345 NORTH FIRST STREET, SAN JOSE	/s/ Philip Mazzara, Attorney-in-Fact	10 Feb 2026	0001399546

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALAB	Common Stock	Award	$0	+11,787	+6.1%	$0.000000	204,084	06 Feb 2026	Direct	F1
holding	ALAB	Common Stock						450,281	06 Feb 2026	By Tate Trust	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent an award of restricted stock units ("RSUs") granted on February 6, 2026 under the Astera Labs, Inc. 2024 Stock Option and Incentive Plan. Such award provides that the RSUs shall vest as to 25% on February 15, 2027 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F2	These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Content

These shares represent an award of restricted stock units ("RSUs") granted on February 6, 2026 under the Astera Labs, Inc. 2024 Stock Option and Incentive Plan. Such award provides that the RSUs shall vest as to 25% on February 15, 2027 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.